71. Teva 2015 ($1,200 million)

Israeli drugmaker Teva agreed to pay US$1.2 billion in May 2015 to end a seven-year FTC investigation into allegations that subsidiary Cephalon engaged in anti-competitive practices by preventing rivals from entering the marketplace.